← All trials
NCT05097209
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 1, 2021
- Primary completion
- Jan 1, 2024
- Completion date
- Jan 1, 2025
- First posted
- Oct 28, 2021
- Last posted
- Oct 28, 2021
- Enrollment
- 458
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Guilin UniversityLead sponsor
- Guangxi Medical UniversityCollaborator
- Guangxi Medical UniversityOverall official - principal investigator
- Wuzhou Red Cross HospitalCollaborator
- Wuzhou Red Cross HospitalOverall official - principal investigator
- Guilin UniversitySponsor investigator
- Lingshan people's HospitalCollaborator
- Lingshan people's HospitalOverall official - principal investigator
- Laibin people's HospitalCollaborator
- Laibin people's HospitalOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.